title: [Clinical analysis of ovarian preservation for stage I endometrial carcinomas in women aged 40 years and younger].
abstract: OBJECTIVE
  To investigate the safety of ovarian preservation for stage I endometrial carcinomas in women aged 40 years and younger.
  
  
  METHODS
  Seventy-five cases of stage I endometrial cancer aged 40 years and younger from Jan 1999 to Jan 2012 were treated in Cancer Hospital, Chinese Academy of Medical Sciences. They were further divided into two groups: 20 patients who underwent ovarian preservation (group A) and 55 patients who underwent oophorectomy (group B). Clinical and pathological recordings of these patients were reviewed and compared.
  
  
  RESULTS
  In the group A, there were 13 patients preserved both ovaries, and 7 patients preserved a single ovary. While there were no significant differences in the age, body mass index, surgical staging, histology, grade, cytology of peritoneal lavage or ascites, and postoperative treatment between two groups (all P > 0.05). The differences in the level of CA125 [25% (5/20) versus 18% (10/55)] and number of patients underwent pelvic lymphadenectomy [35% (7/20) versus 84% (46/55)] were statistically significant between two groups (all P < 0.05). Of seventy-five cases, only two patients relapsed and all survived after a median follow-up time of 31.7 months (range: 0 to 160 months). Kaplan-Meier analysis revealed no difference in overall survival (100.0% versus 100.0%) and disease free survival (90.0% versus 95.5%) between two groups (P = 0.579).
  
  
  CONCLUSIONS
  Ovarian preservation has no statistically significant impact on the survival of young patients with stage Ia, well differentiated endometrial cancer. Large-scale, prospective clinical studies are needed to validate the safety of ovarian preservation for those patients.
authors: Department of Gynecologic Oncology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100021, China.
authors: Lin
authors: L
authors: Li
authors: Department of Gynecologic Oncology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100021, China. Email: wulingying@csco.org.cn.
authors: Lingying
authors: L
authors: Wu
authors: Department of Gynecologic Oncology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100021, China.
authors: Rong
authors: R
authors: Zhang
authors: Department of Gynecologic Oncology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100021, China.
authors: Gongyi
authors: G
authors: Zhang
authors: Department of Gynecologic Oncology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100021, China.
authors: Ning
authors: N
authors: Li
authors: Department of Gynecologic Oncology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100021, China.
authors: Xiaoguang
authors: X
authors: Li
authors: Department of Gynecologic Oncology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100021, China.
authors: Guangwen
authors: G
authors: Yuan
mesh_terms: D000328:Adult; D000367:Age Factors; D018269:Carcinoma, Endometrioid / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D059247:Fertility Preservation; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D008197:Lymph Node Excision; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D059351:Organ Sparing Treatments; D010053:Ovary / Q000601:surgery*; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult